研究单位：[1]Affiliated Cancer Hospital & Institute of Guangzhou Medical University[2]Nanfang Hospital of Southern Medical University[3]Sun Yat-sen University[4]Sixth Affiliated Hospital,Sun Yat-sen University[5]First Affiliated Hospital,Sun Yat-Sen University[6]Guangdong Provincial Hospital of Traditional Chinese Medicine[7]Guangdong Provincial People's Hospital[8]Meizhou People's Hospital[9]First People's Hospital of Foshan[10]Shantou Central Hospital[11]Jiangmen Central Hospital[12]Shenzhen Second People's Hospital[13]Zhongshan People's Hospital,Guangdong,China[14]ZhuHai Hospital[15]Cancer Institute and Hospital,Chinese Academy of Medical Sciences[16]Beijing Hospital[17]Peking University Cancer Hospital & Institute[18]Peking University People's Hospital[19]Fudan University[20]The Second Affiliated Hospital of Chongqing Medical University[21]Chongqing University Cancer Hospital[22]First Affiliated Hospital of Chongqing Medical University[23]Second Affiliated Hospital,School of Medicine,Zhejiang University[24]Wuhan Union Hospital,China[25]Renmin Hospital of Wuhan University[26]Wuhan University[27]Sichuan Provincial People's Hospital[28]West China Hospital[29]The People's Hospital of Leshan[30]People's Hospital of Deyang City[31]Hebei Medical University Fourth Hospital[32]The First Affiliated Hospital of Nanchang University[33]The Affiliated Hospital Of Southwest Medical University[34]The Affiliated Hospital of Xuzhou Medical University[35]People's Hospital of Guangxi[36]The Third People's Hospital of Chengdu[37]The Affiliated Tumor Hospital of Guangxi Medical University
研究目的：
The purpose of this study is to determine the efficacy of adjuvant HIPEC with Mitomycin C after colectomy in the treatment of colorectal cancer patients at high risk of peritoneal carcinomatosis.
